NORWELL, Mass., Oct. 21, 2026 — The National Organization for Rare Disorders (NORD®) has officially announced a new request for applications aimed at implementing two patient registries on its established NORD® IAMRARE® platform. This initiative is made possible through financial support provided by the Rare Disease Cures Accelerator–Data and Analytics Platform (RDCA-DAP®), a collaborative agreement between the Critical Path Institute and the U.S. Food and Drug Administration (FDA).
The announcement represents a significant step forward for rare disease advocacy groups seeking to harness structured, patient-reported data to drive research forward. By expanding the IAMRARE® ecosystem, NORD and its partners aim to equip rare disease patient organizations with the digital infrastructure, regulatory navigation, and operational guidance necessary to collect high-quality natural history data.
The effort builds upon years of groundwork laid by NORD in supporting rare disease nonprofits, many of which operate with limited staff and resources. Research studies directly led and managed by rare disease communities have increasingly become recognized as vital repositories of medical and epidemiological information. Insights generated from studies hosted on the IAMRARE platform have historically played a crucial role in advancing clinical understanding, contributing directly to the development of clinical outcome assessments, updating medical treatment guidelines, and even aiding in at least one FDA approval for a rare disease therapy.
“This opportunity builds on NORD’s work supporting rare disease nonprofits,” says Tracey Sikora, Vice President of Research and Clinical Programs at NORD. “Research studies led by rare disease communities are an important source of data, and insights from IAMRARE-hosted studies have contributed to the development of clinical outcome assessments, updates to treatment guidelines, and at least one FDA approval.”
Under the terms of the new funding opportunity, successful applicants will collaborate closely with NORD starting in April 2027 to design, build, and launch a dedicated patient registry tailored to their specific rare disease community. NORD’s commitment extends beyond software provisioning; the organization will build and host the registry website and deliver comprehensive training to the registry sponsors.
This supportive framework guides sponsors through critical developmental milestones, including the establishment of a registry advisory board, the formulation of a comprehensive study protocol, and the creation and customization of participant surveys. Furthermore, NORD assists sponsors in successfully navigating the complex Institutional Review Board (IRB) process and helps establish clear, standardized criteria for sharing the data collected by the registry with external academic, clinical, and industry researchers.
The initiative is designed to lower the barriers that smaller advocacy groups frequently encounter when attempting to collect regulatory-grade data. By utilizing the pre-existing, secure framework of the IAMRARE platform, organizations can bypass the immense costs and logistical hurdles of custom software development, allowing them to focus immediately on community engagement, participant recruitment, and scientific collaboration.
The request for applications is currently open to eligible rare disease organizations, with the submission window closing on Jan. 10, 2027. Following the evaluation of applications, accepted participants will be formally notified by Feb. 1, 2027. The formal implementation and collaborative development phase for the two chosen registries is scheduled to officially begin in April 2027. Prospective applicants looking to submit their proposals can access the application portal online. Any inquiries regarding the request for applications or the application process can be directed to NORD via email.
The NORD® IAMRARE® platform has established itself as a cornerstone for patient-powered research, currently hosting over 55 live registries sponsored directly by patient advocacy organizations. These registries are specifically designed to capture patient-reported data, providing a direct window into the lived experiences of individuals with rare conditions and tracking disease progression over time.
The underlying funding source for these two new registries, the Rare Disease Cures Accelerator–Data and Analytics Platform (RDCA-DAP®), serves as a centralized and standardized infrastructure designed to support and accelerate rare disease characterization. By integrating diverse data types, the FDA-sponsored initiative aims to streamline and expedite therapy development across the entire rare disease spectrum.
Founded in 1983, the National Organization for Rare Disorders (NORD®) is a leading independent, nonpartisan nonprofit organization dedicated to improving the health and lives of the more than 30 million Americans living with rare diseases. NORD operates through a vast, collaborative network, partnering with more than 350 disease-specific member patient organizations. Additionally, the organization collaborates with 49 designated NORD Rare Disease Centers of Excellence spanning over 170 academic medical centers, research institutions, and children’s hospitals nationwide. Through these strategic partnerships, NORD advances comprehensive care, innovative research, public education, and targeted advocacy to create a better future for people and families impacted by rare conditions.
